Ultimovacs has announced that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer.
DOVACC is organized with two influential European networks of gynecological oncologists; the Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU) – the study sponsor – and the broader European Network of Gynaecological Oncological Trial Groups (ENGOT). With Ultimovacs and AstraZeneca as industry participants, DOVACC will assess whether UV1 enhances progression-free survival in BRCA-negative (BRCA wild type) advanced ovarian cancer in combination with two AstraZeneca drugs, durvalumab and olaparib. Topline data from DOVACC is expected in 2023.
DOVACC
DOVACC will recruit 184 patients across Europe from a network of more than 40 hospitals in around ten European countries coordinated through NSGO-CTU and ENGOT. Innovation Norway has granted Ultimovacs NOK 10 million (approximately $1.2 million) to support the execution of the Phase II DOVACC study.
“The start of recruitment in DOVACC represents another milestone in the expanding clinical program of our lead cancer vaccine UV1,” says Jens Bjørheim, Chief Medical Officer at Ultimovacs. “Working with leading specialized groups around Europe who participate in NSGO-CTU and ENGOT, puts UV1 in the hands of the oncologists who help shape the standard of care in ovarian cancer.”
DOVACC is one of five randomized Phase II clinical trials of Ultimovacs’ telomerase vaccine UV1 in combination with other immunotherapies. The primary outcome measure for DOVACC is progression-free survival for the UV1-durvalumab-olaparib triple combination versus olaparib alone.